Recent studies observed a reduction in signalling with imatinib in cases harboring ABL1-class rearrangments (Roberts et al., 2017), and a case-report on a refractory EBF1-PDGFRB ALL patient showed the complete remission after the addition of imatinib to the conventional chemiotherapy (Weston et al., 2013). This evidence concerns the gene PDGFRB and acute lymphoblastic leukemia.